TX-MAVENIR
16.6.2021 15:02:03 CEST | Business Wire | Press release
Mavenir, the Network Software Provider building the future of networks with cloud-native software that runs on any cloud and transforms the way the world connects, announced today its campus network in Dallas for 4G/5G. The campus demonstrates network integration across a suite of certified solutions, integration with 3rd party vendors for interoperability testing and a new approach to Open Virtualized Radio Access Network (Open vRAN) Citizens Broadband Radio Service (CBRS)/OnGo® Private Network deployments.
Mavenir’s CBRS/OnGo® certified product offering address macro, enterprise and Industry 4.0 use cases. These solutions are being delivered as an end-to-end private network solution or as part of an Open RAN deployment to help Enterprises, Carriers, Value Added Resellers (VARs), System Integrators (SIs) and Wireless Internet Service Providers (WISPs) take advantage of the CBRS spectrum across the United States.
The Mavenir Private Network solution offering, MAVedge , includes radio and core for full CBRS/OnGo® connectivity across varied applications:
-
MAVair
:
- A full suite of 4G/5G FCC and OnGo® certified Citizen Broadband Service Devices (CBSD): for both indoor and outdoor applications, zero-touch provisioning and analytics.
- Smart poles which include a wide range of capabilities including electric vehicle (EV) charger station, large light-emitting diode (LED) display unit for advertisements, camera, street light and weather station / environmental sensor.
- CBRS/OnGo® Open vRAN: designed with cloud-native virtualization techniques, enables the RAN to flex and adapt based on usage and coverage.
- MAVcore : 4G/5G Evolved Packet Core (EPC), delivered on premise, hybrid and cloud hosted CBRS/OnGo® as a service.
As a pioneer in Open RAN , Mavenir has completed interoperability testing with 3rd party solution providers, including multiple Customer Premises Equipment (CPE), to validate and showcase vendor interoperability and demonstrate how the ecosystem deploys a successful and functional Open vRAN-based private network. The Mavenir campus hosts a private CBRS/OnGo® network for indoor and outdoor interoperability showcasing network Internet of Things (IoT) capabilities, radios and antennas deployed across a variety of smart use cases including smart light poles. Additionally, the campus demonstrates throughput, handover, and full carrier aggregation across both General Authorized Access (GAA) and Priority Access License (PAL) spectrum
“Mavenir is committed to driving interoperability by growing the CBRS/OnGo® ecosystem with device vendors, application providers and network connectivity players”, said Mavenir’s Aniruddho Basu, SVP and GM of Emerging Business. “The Mavenir 4G/5G Campus offers a network showcase Open vRAN and demonstrates open interoperability, test and implementation of end-to-end user applications, including IoT sensor and device connectivity. Putting Mavenir on the map for municipalities, enterprises and Communication Service Providers (CSP) looking to explore the possibilities available by operating a private network.”
About Mavenir:
Mavenir is building the future of networks and pioneering advanced technology, focusing on the vision of a single, software-based automated network that runs on any cloud. As the industry's only end-to-end, cloud-native network software provider, Mavenir is focused on transforming the way the world connects, accelerating software network transformation for 250+ Communications Service Providers in over 120 countries, which serve more than 50% of the world’s subscribers. www.mavenir.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20210616005097/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release
Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release
News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi
Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo
IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 12:50:00 CEST | Press release
Transaction advances portfolio transformation, sharpens focus on higher-growth, higher-margin businesses, strengthens balance sheet, and enhances value creation for shareholders IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio tr
BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 12:00:00 CEST | Press release
Data represents the longest reported follow-up for a next-generation BTK inhibitor in CLL, showing sustained disease control and benefit that extends beyond first-line therapyBRUKINSA plus next-generation BCL2 inhibitor sonrotoclax (ZS) delivered deep, durable, and rapid uMRD responses, raising the bar for potential time-limited treatments in CLLData reinforce BeOne’s leadership in CLL and the strength of its foundational hematology franchise BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 pati
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom